Multiple Sclerosis Drugs

Everything

Homepage | Elan
www.elan.com
Elan Careers Search Company About Us Vision Management Team Board of Directors Careers Benefits Overview Job Search Contact Us Funding Requests Medical Education Grants Charitable Contributions, Sponsorships and Patient Education Program Requests Therapies Overview Disease Areas Alzheimer's Disease

New multiple sclerosis drugs set to capture market share | Pharma Asia
www.pharmaasia.com | Jul 19, 2010
The Russian approval of Merck Serono’s Movectro (oral cladribine) is a landmark in the treatment for relapse-remitting multiple sclerosis (RRMS) patients, as it becomes the world’s first oral disease-modifying MS therapy to be granted marketing authorisation beating Novartis’s Gilenia

Prospects of Multiple Sclerosis Drug Market Globally Available through Bharatbook
www.prlog.org | May 3, 2010
Prospects of Multiple Sclerosis Drug Market Globally Available through Bharatbook. Bharatbook added a new report on "Global Multiple Sclerosis Drug Market 2010-2025" which gives the global R&D developments in the Multiple Sclerosis Drugs Market.

Ambrx and Merck Serono Form Multiple Sclerosis Drug Development Alliance
www.dddmag.com
Ambrx Inc. and Merck Serono announced a global strategic collaboration to develop and commercialize Ambrx’s ARX424 preclinical product candidate for the treatment of multiple sclerosis.

'World Pre-filled Syringe Technology Revenues Will Reach $3.9bn in 2015' Says Visiongain Report |
www.sys-con.com | Jun 22, 2011
SYS-CON Media, NJ, The world's leading i-technology media company on breaking technology news.

Biogen Idec Receives Fast Track Designation For Multiple Sclerosis Drug - Pharmaceutical Business
www.pharmaceutical-business-review.com | Jul 8, 2009
Trial designed to evaluate efficacy and safety of PEGylated interferon beta-1a in patients with RMS

Momenta Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com | Feb 9, 2012
< p > Momenta Pharmaceuticals Inc. ( < a href='http://seekingalpha.com/symbol/mnta' title='Momenta Pharmaceuticals, Inc.' > MNTA < /a > ) < /p > < p > Q4 2011 Earnings Call < /p > < p > February 9, 2012 10:00 am ET < /p > < p > < strong > Executives < /strong > < /p > < p > Beverly Holley -

Alarm over drugs fast tracking
www.allaboutmedicalsales.com | Feb 17, 2006
Alarm over drugs fast tracking. Fast tracking new drugs could have a negative effect on patients in the longer term, a senior doctor in Britain has claimed.

Medical News: CMSC-ACTRIMS: Fingolimod Supports ADLs in MS - in Meeting Coverage, CMSC-ACTRIMS from
www.medpagetoday.com | Jun 7, 2010
SAN ANTONIO -- Multiple sclerosis patients who took the oral investigational agent fingolimod were better able to maintain activities of daily living over a year than those treated with injected inter

Teva Pharmaceutical Industries Limited Q2 Profit Beats Estimates, Sales in Line - News, Search
www.biospace.com | Jul 27, 2010
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA - News) today reported results for the quarter ended June 30, 2010.</p><p>Second Quarter Highlights:</p><p>* Quarterly net sales of $3.8 billion, reflecting organic growth of 12%, compared to the comparable period in